Tests a lifestyle program for weight and inflammation in young women with obesity
Tests a lifestyle program in young women with obesity.
Plain-language title generated from the registry record
Registry title: Redefining BMI: The Body, Mind, and Inflammation Trial
Key facts
- Where
- Richmond, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-25 with a BMI of 25-50 kg/m^2 to test two lifestyle programs for reducing body fat.
- Age
- 18-25 years
- Sex
- Women only
- Disease stage
- BMI of 25-50 kg/m^2
- Earlier treatment
- Cannot be in a weight loss program or taking weight loss medication now. Cannot have lost more than 5% of body weight in the past 3 months.
Main reasons for not taking part
- Currently pregnant or breastfeeding
- Type 1 or type 2 diabetes, or impaired fasting blood glucose
- Use of medications that may affect weight or metabolism, or anti-inflammatory medications, now or in the past 3 months
- History of anorexia nervosa or bulimia nervosa, or related behaviors in the past 3 months
- Unable to read and speak English
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 25 years old?
Source: NCT06532747, who can take part
Where in United States
- Virginia Commonwealth UniverstityRichmond, United StatesContact: Vivian Hunter, MSTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Virginia Commonwealth University
- Trial code
- NCT06532747
- Record updated
- 6 May 2026
- Original description
Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.Read full original descriptionShow less
Redefining BMI: The Body, Mind, and Inflammation Trial
Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.
Inclusion: Ages 18-25 years; Body mass index (BMI) 25-50 kg/m\^2; Female.
Exclusion: Current involvement in a weight loss program or current use of weight loss medication; Lost >5% of their body weight in the previous 3 months; Current or recent (during the past 3 months) use of medications that may impact weight or metabolic function; Current or recent (during the past 3 months) use of anti-inflammatory medications; Report of diagnosis or history of Anorexia Nervosa or Bulimia Nervosa, or any compensatory behaviors within the previous 3 months; Uncontrolled medical conditions that may pose a safety issue given the recommendations for the diet and unsupervised physical activity; Diagnosis of type 1 diabetes; Rheumatologic and gastrointestinal conditions associated with severe systemic inflammation; Medical conditions resulting in known perturbations in the hypothalamic-pituitary-adrenal axis; Report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness; Hospitalization for depression or other psychiatric disorder within the past 12 months; Uncontrolled bipolar disorder or psychotic disorder; Unwilling to be randomized to either study condition; Diagnosis of type 2 diabetes and/or impaired fasting blood glucose; Currently pregnant or lactating; Current suicidal intent; Planning to move from the area within the study period; Unable to read and speak English.